NCT02222688View on ClinicalTrials.gov

UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 8, 2014

Primary Completion Date

October 10, 2017

Study Completion Date

May 1, 2018

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

cirmtuzumab

Trial Locations (1)

92093

UCSD Moores Cancer Center, La Jolla

All Listed Sponsors
lead

Thomas Kipps

OTHER

NCT02222688 - UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter